Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Karabulut, Sevgia; b | Kaya, Zehraa; c | Amuran, Gökçe Gūllūa | Peker, Irema | Özmen, Tolgad | Gūllūoḡlu, Bahadır M.d | Kaya, Handane | Erzik, Cana | Ōzer, Ayşea | Akkiprik, Mustafaa; *
Affiliations: [a] Marmara University, School of Medicine, Medical Biology Department, Istanbul, Turkey | [b] Bayburt University, Health Services Vocational School, Bayburt, Turkey | [c] Yüzüncü Yıl University, School of Medicine, Medical Biology Department, Van, Turkey | [d] Marmara University, School of Medicine, General Surgery Department, Istanbul, Turkey | [e] Marmara University, School of Medicine, Pathology Department, Istanbul, Turkey
Correspondence: [*] Corresponding author: Mustafa Akkiprik, Marmara University, School of Medicine, Department of Medical Biology, Başıbüyük Mah., Maltepe Başıbüyük Yolu Sok., No: 9/1, 34854 Maltepe, Istanbul, Turkey. Tel: +90 216 421 22 22/1566; E-mail: makkiprik@marmara.edu.tr
Abstract: BACKGROUND:The insulin-like growth factor binding protein5 (IGFBP5) is often dysregulated in human cancers and considered neither a tumor suppressor nor an oncogene. OBJECTIVE:We aim to examine the reason of the changeable gene regulation of IGFBP5 in the case of methylation in breast cancer. METHODS:We used methyl-specific polymerase (MSP) chain reaction to detect CpG methylation of IGFBP5 promoter and exon-I in breast cancer and adjacent tissues. Gene expression is evaluated by quantative polymerase chain reaction (qPCR). RESULTS:IGFBP5 methylation was detected in 24 of 58 (41%) and 54 of 56 (96.5%) promoter and exon-I site respectively in tumor tissues. In adjacent tissues 17 of 58 (29%) and 53 of 56 (96.5%) was methylated. IGFBP5 expression was higher estrogene receptor (ER)(+) than ER(−) patients (p = 0.0549). Beside, we found a positive correlation between the expression of IGFBP5 and G2 tumor grade (p = 0.0131). However, no correlation was observed between IGFBP5 expression and age, menopause or the presence of lymph node metastasis (p > 0.05). CONCLUSIONS:In summary, our results showed that IGFBP5 promoter and exon-I methylation did not have any differences between tumor and adjacent tissues so that IGFBP5 methylation did not change IGFBP5 gene regulation in breast cancer. This is the first study investigating the IGFBP5 gene methylation in breast cancer.
Keywords: IGFBP5, breast cancer, methylation, MSP, promoter
DOI: 10.3233/BD-160234
Journal: Breast Disease, vol. 36, no. 4, pp. 123-131, 2016
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl